BioMimetic Therapeutics, Inc. to Highlight Corporate Activities at Deutsche Bank Small and Mid Cap Growth Conference
Franklin, Tenn. – February 14, 2008 - BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) announced today that Larry Bullock, CFO, will provide an update of corporate activities at the Deutsche Bank Small and Mid Cap Growth Conference. The presentation will take place in Salon 1 at the Ritz Carlton in Naples, Fl. on Thursday, February 14 at 10:40 a.m. Eastern Standard Time.
A live audio webcast of the presentation will be available at http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=BMTI&item_id=1732924 and on the Company's website at www.biomimetics.com. The webcast will be accessible for a period of at least 30 days.
About BioMimetic Therapeutics
BioMimetic Therapeutics, Inc. is developing and commercializing bio-active recombinant protein-device combination products for the healing of musculoskeletal injuries and disease, including orthopedic, spine and sports injury applications. BioMimetic received marketing approval from the FDA for its first product, GEM 21S®, as a grafting material for bone and periodontal regeneration following completion of human clinical trials, which demonstrated the safety and efficacy of its platform technology in this indication. Additionally, the Company has clinical trials ongoing with its product candidates GEM OS1 and GEM OS2 in multiple orthopedic bone healing indications including the treatment of foot and ankle fusions and the stimulation of healing of fractures of the arm. The Company's previously approved product and lead product candidates all combine recombinant protein therapeutics with tissue specific scaffolds to actively stimulate tissue healing and regeneration.
GEM 21S® is a registered trademark of Luitpold Pharmaceuticals, Inc., who owns and markets that product through its Osteohealth Company division.
For further information, visit www.biomimetics.com or contact Kearstin Patterson, associate director of corporate communications, at 615-236-4419.
###
Back to Headlines |
